Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653).

Sadeghi S, Groshen SG, Tsao-Wei DD, Parikh R, Mortazavi A, Dorff TB, Kefauver C, Hoimes C, Doyle L, Quinn DI, Newman E, Lara PN Jr.

J Clin Oncol. 2019 Oct 10;37(29):2682-2688. doi: 10.1200/JCO.19.00861. Epub 2019 Aug 7.

PMID:
31390274
2.

Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC).

Dorff TB, Quinn DI, Pinski JK, Goldkorn A, Sadeghi S, Tsao-Wei D, Groshen S, Kuhn P, Gross ME.

Clin Genitourin Cancer. 2019 Aug;17(4):241-247.e1. doi: 10.1016/j.clgc.2019.02.010. Epub 2019 Mar 19.

PMID:
31227432
3.

The Evolving Role of Prostate-Specific Membrane Antigen-Based Diagnostics and Therapeutics in Prostate Cancer.

Dorff TB, Fanti S, Farolfi A, Reiter RE, Sadun TY, Sartor O.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:321-330. doi: 10.1200/EDBK_239187. Epub 2019 May 17. Review.

4.

Impact of timing of administration of bone supportive therapy on pain palliation from radium-223.

Yap KK, Wong W, Ji L, Groshen S, Quinn DI, Bryce AH, Dorff TB.

Cancer Treat Res Commun. 2019;18:100114. doi: 10.1016/j.ctarc.2018.100114. Epub 2018 Nov 10.

PMID:
30529990
5.

Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma.

Liu M, Zhang L, Li H, Hinoue T, Zhou W, Ohtani H, El-Khoueiry A, Daniels J, O'Connell C, Dorff TB, Lu Q, Weisenberger DJ, Liang G.

Hepatology. 2018 Oct;68(4):1412-1428. doi: 10.1002/hep.30091.

6.

Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921.

Hussain M, Tangen CM, Thompson IM Jr, Swanson GP, Wood DP, Sakr W, Dawson NA, Haas NB, Flaig TW, Dorff TB, Lin DW, Crawford ED, Quinn DI, Vogelzang NJ, Glode LM.

J Clin Oncol. 2018 May 20;36(15):1498-1504. doi: 10.1200/JCO.2017.76.4126. Epub 2018 Apr 6. Erratum in: J Clin Oncol. 2018 Jul 10;36(20):2131.

7.

Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial.

Dawson JK, Dorff TB, Todd Schroeder E, Lane CJ, Gross ME, Dieli-Conwright CM.

BMC Cancer. 2018 Apr 3;18(1):368. doi: 10.1186/s12885-018-4306-9.

8.

Bone-targeted therapies to reduce skeletal morbidity in prostate cancer.

Dorff TB, Agarwal N.

Asian J Androl. 2018 May-Jun;20(3):215-220. doi: 10.4103/aja.aja_12_18. Review.

9.

Baseline Glomerular Filtration Rate and Cisplatin- Induced Renal Toxicity in Urothelial Cancer Patients.

Loh JM, Tran AL, Ji L, Groshen S, Daneshmand S, Schuckman A, Quinn DI, Dorff TB.

Clin Genitourin Cancer. 2017 Sep 6. pii: S1558-7673(17)30271-9. doi: 10.1016/j.clgc.2017.08.016. [Epub ahead of print]

PMID:
28958673
10.

Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870).

Pili R, Quinn DI, Hammers HJ, Monk P, George S, Dorff TB, Olencki T, Shen L, Orillion A, Lamonica D, Fragomeni RS, Szabo Z, Hutson A, Groman A, Perkins SM, Piekarz R, Carducci MA.

Clin Cancer Res. 2017 Dec 1;23(23):7199-7208. doi: 10.1158/1078-0432.CCR-17-1178. Epub 2017 Sep 22.

11.

Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer.

Dorff TB, Longmate JA, Pal SK, Stadler WM, Fishman MN, Vaishampayan UN, Rao A, Pinksi JK, Hu JS, Quinn DI, Lara PN Jr.

Cancer. 2017 Dec 1;123(23):4566-4573. doi: 10.1002/cncr.30942. Epub 2017 Aug 22.

12.

Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC).

Gross ME, Dorff TB, Quinn DI, Diaz PM, Castellanos OO, Agus DB.

Clin Genitourin Cancer. 2017 Jul 14. pii: S1558-7673(17)30200-8. doi: 10.1016/j.clgc.2017.07.003. [Epub ahead of print]

PMID:
28826933
13.

Chemotherapy for oligometastatic prostate cancer.

Dorff TB, Sweeney CJ.

Curr Opin Urol. 2017 Nov;27(6):553-558. doi: 10.1097/MOU.0000000000000446. Review.

PMID:
28817399
14.

Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment.

Yu SS, Ballas LK, Skinner EC, Dorff TB, Sadeghi S, Quinn DI.

Clin Adv Hematol Oncol. 2017 Jul;15(7):543-551. Review.

PMID:
28749918
15.

Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease.

Yu SS, Dorff TB, Ballas LK, Sadeghi S, Skinner EC, Quinn DI.

Clin Adv Hematol Oncol. 2017 Jun;15(6):466-477. Review.

PMID:
28749907
16.

A pilot randomised controlled trial of a periodised resistance training and protein supplementation intervention in prostate cancer survivors on androgen deprivation therapy.

Kiwata JL, Dorff TB, Todd Schroeder E, Salem GJ, Lane CJ, Rice JC, Gross ME, Dieli-Conwright CM.

BMJ Open. 2017 Jul 10;7(7):e016910. doi: 10.1136/bmjopen-2017-016910.

17.

A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer.

Yu SS, Athreya K, Liu SV, Schally AV, Tsao-Wei D, Groshen S, Quinn DI, Dorff TB, Xiong S, Engel J, Pinski J.

Clin Genitourin Cancer. 2017 Dec;15(6):742-749. doi: 10.1016/j.clgc.2017.06.002. Epub 2017 Jun 8.

PMID:
28668277
18.

Current Management Strategy for Penile Cancer and Future Directions.

Dorff TB, Ballas LK, Schuckman AK.

Curr Oncol Rep. 2017 Aug;19(8):54. doi: 10.1007/s11912-017-0615-4. Review.

PMID:
28664471
19.

Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial.

Alumkal JJ, Chowdhury S, Loriot Y, Sternberg CN, de Bono JS, Tombal B, Carles J, Flaig TW, Dorff TB, Phung, Forer D, Noonberg SB, Mansbach H, Beer TM, Higano CS.

Clin Genitourin Cancer. 2017 Oct;15(5):610-617.e3. doi: 10.1016/j.clgc.2017.02.007. Epub 2017 Mar 3.

PMID:
28344102
20.

Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection.

Yu SS, Quinn DI, Dorff TB.

Onco Targets Ther. 2016 Sep 23;9:5825-5837. eCollection 2016. Review.

21.

Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial.

Rini BI, Dorff TB, Elson P, Rodriguez CS, Shepard D, Wood L, Humbert J, Pyle L, Wong YN, Finke JH, Rayman PA, Larkin JM, Garcia JA, Plimack ER.

Lancet Oncol. 2016 Sep;17(9):1317-24. doi: 10.1016/S1470-2045(16)30196-6. Epub 2016 Aug 3.

PMID:
27498080
22.

A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients.

Kiwata JL, Dorff TB, Schroeder ET, Gross ME, Dieli-Conwright CM.

Prostate Cancer Prostatic Dis. 2016 Dec;19(4):323-332. doi: 10.1038/pcan.2016.25. Epub 2016 Jun 28. Review.

23.

Safety and feasibility of fasting in combination with platinum-based chemotherapy.

Dorff TB, Groshen S, Garcia A, Shah M, Tsao-Wei D, Pham H, Cheng CW, Brandhorst S, Cohen P, Wei M, Longo V, Quinn DI.

BMC Cancer. 2016 Jun 10;16:360. doi: 10.1186/s12885-016-2370-6.

24.

Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors.

Feldman DR, Hu J, Dorff TB, Lim K, Patil S, Woo KM, Carousso M, Hughes A, Sheinfeld J, Bains M, Daneshmand S, Ketchens C, Bajorin DF, Bosl GJ, Quinn DI, Motzer RJ.

J Clin Oncol. 2016 Jul 20;34(21):2478-83. doi: 10.1200/JCO.2016.66.7899. Epub 2016 May 16.

25.

Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile Cancer.

Dorff TB, Schuckman AK, Schwartz R, Rashad S, Bulbul A, Cai J, Pinski J, Ma Y, Danenberg K, Skinner E, Quinn DI.

Clin Genitourin Cancer. 2016 Oct;14(5):450-456.e1. doi: 10.1016/j.clgc.2016.01.013. Epub 2016 Feb 6.

PMID:
26935231
26.

Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science.

Nussbaum N, George DJ, Abernethy AP, Dolan CM, Oestreicher N, Flanders S, Dorff TB.

Prostate Cancer Prostatic Dis. 2016 Jun;19(2):111-21. doi: 10.1038/pcan.2015.42. Epub 2016 Feb 2. Review.

27.

Prostatectomy at high-volume centers improves outcomes and lowers the costs of care for prostate cancer.

Barzi A, Klein EA, Dorff TB, Quinn DI, Sadeghi S.

Prostate Cancer Prostatic Dis. 2016 Mar;19(1):84-91. doi: 10.1038/pcan.2015.56. Epub 2015 Dec 15.

PMID:
26666409
28.

A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan.

Brandhorst S, Choi IY, Wei M, Cheng CW, Sedrakyan S, Navarrete G, Dubeau L, Yap LP, Park R, Vinciguerra M, Di Biase S, Mirzaei H, Mirisola MG, Childress P, Ji L, Groshen S, Penna F, Odetti P, Perin L, Conti PS, Ikeno Y, Kennedy BK, Cohen P, Morgan TE, Dorff TB, Longo VD.

Cell Metab. 2015 Jul 7;22(1):86-99. doi: 10.1016/j.cmet.2015.05.012. Epub 2015 Jun 18.

29.

Relapsed and refractory germ cell tumors: Finessing the rough end of a beautiful story.

Dorff TB, Hu J, Quinn DI.

Urol Oncol. 2015 Aug;33(8):341-2. doi: 10.1016/j.urolonc.2015.05.023. Epub 2015 Jun 18. No abstract available.

PMID:
26094170
30.

Hitting Prostate Cancer Where It Hurts: Maximizing Control of Osseous Metastases.

Dorff TB, Pal SK.

Oncology (Williston Park). 2015 Jun;29(6):424, 426. No abstract available.

31.

Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer?

Dorff TB, Gross ME.

Am Soc Clin Oncol Educ Book. 2015:e270-3. doi: 10.14694/EdBook_AM.2015.35.e270.

32.

Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review.

Vashistha V, Quinn DI, Dorff TB, Daneshmand S.

BMC Cancer. 2014 Dec 16;14:966. doi: 10.1186/1471-2407-14-966. Review.

33.

Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors.

Piatek CI, Raja GL, Ji L, Gitlitz BJ, Dorff TB, Quinn DI, Hu J, El-Khoueiry AB, Pham HQ, Roman L, Garcia AA.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1227-34. doi: 10.1007/s00280-014-2600-z. Epub 2014 Nov 6.

PMID:
25374407
34.

Phase I, dose-escalation study of the targeted cytotoxic LHRH analog AEZS-108 in patients with castration- and taxane-resistant prostate cancer.

Liu SV, Tsao-Wei DD, Xiong S, Groshen S, Dorff TB, Quinn DI, Tai YC, Engel J, Hawes D, Schally AV, Pinski JK.

Clin Cancer Res. 2014 Dec 15;20(24):6277-83. doi: 10.1158/1078-0432.CCR-14-0489. Epub 2014 Oct 2.

35.

A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer.

Dorff TB, Groshen S, Tsao-Wei DD, Xiong S, Gross ME, Vogelzang N, Quinn DI, Pinski JK.

Prostate Cancer Prostatic Dis. 2014 Dec;17(4):359-65. doi: 10.1038/pcan.2014.37. Epub 2014 Sep 23.

36.

Salvage chemotherapy for refractory germ cell tumors.

Dorff TB, Hu JS, Quinn DI.

Oncology (Williston Park). 2014 Jun;28(6):498-500. Review. No abstract available.

PMID:
25134324
37.

Prolonged fasting reduces IGF-1/PKA to promote hematopoietic-stem-cell-based regeneration and reverse immunosuppression.

Cheng CW, Adams GB, Perin L, Wei M, Zhou X, Lam BS, Da Sacco S, Mirisola M, Quinn DI, Dorff TB, Kopchick JJ, Longo VD.

Cell Stem Cell. 2014 Jun 5;14(6):810-23. doi: 10.1016/j.stem.2014.04.014. Erratum in: Cell Stem Cell. 2016 Feb 4;18(2):291-2.

38.

Concurrent chemoradiotherapy for men with locally advanced penile squamous cell carcinoma.

Pond GR, Milowsky MI, Kolinsky MP, Eigl BJ, Necchi A, Harshman LC, Di Lorenzo G, Dorff TB, Lee RJ, Sonpavde G.

Clin Genitourin Cancer. 2014 Dec;12(6):440-6. doi: 10.1016/j.clgc.2014.03.009. Epub 2014 Mar 27.

PMID:
24787971
39.

Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy.

Pond GR, Di Lorenzo G, Necchi A, Eigl BJ, Kolinsky MP, Chacko RT, Dorff TB, Harshman LC, Milowsky MI, Lee RJ, Galsky MD, Federico P, Bolger G, DeShazo M, Mehta A, Goyal J, Sonpavde G.

Urol Oncol. 2014 May;32(4):501-8. doi: 10.1016/j.urolonc.2013.10.007. Epub 2013 Dec 12.

PMID:
24332646
40.

Durable complete remission from castration-resistant prostate cancer with sipuleucel-T after estrogen withdrawal.

Dorff TB, Wilkins C, Hepgur M, Quinn DI.

Clin Genitourin Cancer. 2014 Apr;12(2):e55-8. doi: 10.1016/j.clgc.2013.11.006. Epub 2013 Nov 14. No abstract available.

PMID:
24331572
41.

Novel tyrosine kinase inhibitors for renal cell carcinoma.

Dorff TB, Pal SK, Quinn DI.

Expert Rev Clin Pharmacol. 2014 Jan;7(1):67-73. doi: 10.1586/17512433.2014.862496. Epub 2013 Dec 2. Review.

PMID:
24308791
42.

Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: a critical analysis of 1,994 patients.

Mitra AP, Skinner EC, Schuckman AK, Quinn DI, Dorff TB, Daneshmand S.

Urol Oncol. 2014 Jan;32(1):52.e1-9. doi: 10.1016/j.urolonc.2013.08.007. Epub 2013 Nov 13.

PMID:
24239476
43.

Epidermal growth factor receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3 cases.

Brown A, Ma Y, Danenberg K, Schuckman AK, Pinski JK, Pagliaro LC, Quinn DI, Dorff TB.

Urology. 2014 Jan;83(1):159-65. doi: 10.1016/j.urology.2013.08.074. Epub 2013 Nov 12. Erratum in: Urology. 2014 Jun;83(6):1446.

PMID:
24238569
44.

Clinicopathologic characteristics and outcomes of penile cancer treated at tertiary care centers in the Western United States.

Jayaratna IS, Mitra AP, Schwartz RL, Dorff TB, Schuckman AK.

Clin Genitourin Cancer. 2014 Apr;12(2):138-42. doi: 10.1016/j.clgc.2013.09.006. Epub 2013 Sep 27.

PMID:
24210829
45.

Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer.

Dorff TB, Tsao-Wei DD, Groshen S, Boswell W, Goldkorn A, Xiong S, Quinn DI, Pinski JK.

Clin Genitourin Cancer. 2013 Dec;11(4):416-22. doi: 10.1016/j.clgc.2013.07.011. Epub 2013 Oct 4.

PMID:
24099865
46.

Weighing the evidence for immune therapy and targeted therapy in renal cancer and melanoma.

Dorff TB, Wong MK.

Oncology (Williston Park). 2013 Jul;27(7):691-2, 694. No abstract available.

47.

Tivozanib in the treatment of renal cell carcinoma.

Hepgur M, Sadeghi S, Dorff TB, Quinn DI.

Biologics. 2013;7:139-48. doi: 10.2147/BTT.S32958. Epub 2013 Jun 11.

48.

Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer.

Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Pinski JK, Quinn DI.

J Nucl Med. 2013 Aug;54(8):1195-201. doi: 10.2967/jnumed.112.114116. Epub 2013 Jun 19.

49.

Current role of neoadjuvant and adjuvant systemic therapy for high-risk localized prostate cancer.

Dorff TB, Glode LM.

Curr Opin Urol. 2013 Jul;23(4):366-71. doi: 10.1097/MOU.0b013e328361d467. Review.

50.

Speeding dating for docetaxel and recent debutantes in castration-resistant prostate cancer: 'plus or minus' may be a minus.

Dorff TB, Quinn DI.

Ann Oncol. 2013 Feb;24(2):270-2. doi: 10.1093/annonc/mds641. No abstract available.

PMID:
23341479

Supplemental Content

Loading ...
Support Center